Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

the EMBODY Investigator Group

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials'. Together they form a unique fingerprint.

Medicine & Life Sciences